NEWHALL CHARLES W III 4
4 · SUPERNUS PHARMACEUTICALS, INC. · Filed Nov 12, 2024
Insider Transaction Report
Form 4
NEWHALL CHARLES W III
Director
Transactions
- Exercise/Conversion
Common Stock
2024-11-11$9.13/sh+20,000$182,600→ 140,975 total - Sale
Common Stock
2024-11-11$36.24/sh−10,700$387,768→ 130,275 total - Exercise/Conversion
Director Stock Option (Right to Buy)
2024-11-11−20,000→ 0 totalExercise: $9.13From: 2016-03-03Exp: 2025-03-03→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $36.46. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.